
Ask a doctor about a prescription for MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION
Leaflet: information for the user
Mometasona Mede1 mg/g cutaneous solution EFG
mometasone furoate
Read the entire leaflet carefully before starting to use the medicine, as it contains important information for you.
Contents of the leaflet:
This medicine contains mometasone furoate as the active ingredient, which belongs to the group of topical glucocorticoids and acts as an anti-inflammatory and antipruritic in skin conditions.
Mometasona Mede is indicated for the relief of inflammatory and pruritic manifestations (with itching or scratching) of dermatoses that respond to treatment with glucocorticoids, such as psoriasis (a skin disease characterized by scaling) and atopic dermatitis (a chronic skin condition characterized by the appearance of scaly eruptions, accompanied by itching).
Do not use Mometasona Mede
If you are allergic to the active ingredient mometasone furoate, to other corticosteroids, or to any of the other components of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to use Mometasona Mede.
Be particularly careful with this medicine when treating large body surfaces, when using occlusive dressings, in long-term treatments, or when applying it to the skin of the face or skin folds. Avoid contact with the eyes. In case of accidental contact, wash your eyes with plenty of water.
Contact your doctor if you experience blurred vision or other visual disturbances.
Other medicines and Mometasona Mede
Tell your doctor or pharmacist if you are using or have recently used or may need to use any other medicine, including those purchased without a prescription.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. Mometasona Mede should be avoided in pregnant or breastfeeding women, except on medical prescription.
Driving and using machines
There are no known data to suggest that the product may affect the ability to drive or operate machinery.
Mometasona Mede contains propylene glycol
This medicine contains 300 mg of propylene glycol per gram of cutaneous solution.
Propylene glycol may cause skin irritation.
This medicine contains propylene glycol; do not use on open wounds or large areas of damaged skin (such as burns) without consulting your doctor or pharmacist first.
Follow the administration instructions for this medicine exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Your doctor will indicate the duration of treatment with this medicine. Do not stop treatment on your own.
If you think the effect of this medicine is too strong or too weak, tell your doctor or pharmacist.
Mometasona Mede is for cutaneous use (applied to the skin or scalp).
The recommended dose is:
Apply a few drops of Mometasona Mede to the affected areas once a day and gently massage until it disappears.
Do not cover or bandage the treated area unless your doctor has indicated it.
If you use more Mometasona Mede than you should:
If you have used more Mometasona Mede than indicated, consult your doctor or pharmacist immediately.
In case of overdose or accidental ingestion, go to a medical center or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount used.
If you forget to use Mometasona Mede:
Do not use a double dose to make up for forgotten doses; continue with the usual routine, and if you have forgotten many doses, consult your doctor or pharmacist immediately.
If you stop treatment with Mometasona Mede
Avoid sudden cessation of treatment. As with all highly active steroids, treatment should be discontinued gradually.
If you have any other doubts about using this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can have side effects, although not everyone gets them.
The following side effects have been reported and are classified according to their frequency:
Very common: (may affect more than 1 in 10 people) Common: (may affect up to 1 in 10 people).
Uncommon: (may affect up to 1 in 100 people).
Rare: (may affect up to 1 in 1,000 people).
Very rare: (may affect up to 1 in 10,000 people)
Frequency not known: (cannot be estimated from the available data)
Disorders of the skin and subcutaneous tissue:
|
Endocrine disorders:
|
Ocular disorders: Frequency not known: blurred vision |
If you think any of the side effects you are experiencing is serious or if you notice any side effect not mentioned in this leaflet, tell your doctor or pharmacist.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
No special storage conditions are required.
Expiry date: Do not use this medicine after the expiry date stated on the label and carton, after EXP. The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the containers and medicines you no longer need at the
collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This will help protect the environment.
Composition of Mometasona Mede
The active ingredient is mometasone furoate. Each gram of cutaneous solution contains 1 milligram of mometasone furoate.
The other components are: isopropyl alcohol, propylene glycol (E-1520), hydroxypropyl cellulose, sodium dihydrogen phosphate dihydrate, phosphoric acid, and purified water.
Appearance of the product and package contents
Mometasona Mede 1 mg/g cutaneous solution is a clear and colorless solution.
This medicine is presented in bottles of 30 and 60 ml of cutaneous solution. Marketing authorization holder and manufacturer: Laboratorio Reig Jofré S.A. Gran Capitán, 10 08970 Sant Joan Despí (Barcelona) Spain Date of the last revision of this leaflet: October 2020 Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/ |
The average price of MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION in November, 2025 is around 4.98 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION – subject to medical assessment and local rules.